The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; none of the 1 sources its claims cite is checked for support yet.
Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers
Open accessAbstract
Synapse deterioration underlying severe memory loss in early Alzheimer's disease (AD) is thought to be caused by soluble amyloid beta (Aβ) oligomers. Mechanistically, soluble Aβ oligomers, also referred to as Aβ-derived diffusible ligands (ADDLs), act as highly specific pathogenic ligands, binding to sites localized at particular synapses. This binding triggers oxidative stress, loss of synaptic spines, and ectopic redistribution of receptors critical to plasticity and memory. We report here the existence of a protective mechanism that naturally shields synapses against ADDL-induced deterioration. Synapse pathology was investigated in mature cultures of hippocampal neurons. Before spine loss, ADDLs caused major downregulation of plasma membrane insulin receptors (IRs), via a mechanism sensitive to calcium calmodulin-dependent kinase II (CaMKII) and casein kinase II (CK2) inhibition. Most significantly, this loss of surface IRs, and ADDL-induced oxidative stress and synaptic spine deterioration, could be completely prevented by insulin. At submaximal insulin doses, protection was potentiated by rosiglitazone, an insulin-sensitizing drug used to treat type 2 diabetes. The mechanism of insulin protection entailed a marked reduction in pathogenic ADDL binding. Surprisingly, insulin failed to block ADDL binding when IR tyrosine kinase activity was inhibited; in fact, a significant increase in binding was caused by IR inhibition. The protective role of insulin thus derives from IR signaling-dependent downregulation of ADDL binding sites rather than ligand competition. The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In mature hippocampal cultures, insulin signaling prevented Aβ oligomer (ADDL) binding, oxidative stress, insulin receptor loss, and spine degeneration, with protection requiring insulin receptor tyrosine kinase activity rather than simple ligand competition. Rosiglitazone potentiated submaximal insulin’s protection, suggesting that enhancing CNS insulin signaling may defend synapses against Alzheimer’s-linked toxins.
Key findings
- ADDLs caused loss of surface insulin receptors (IRs): surface-exposed IR levels decreased by 22% after 30 min and 68% after 3 h of exposure to 100 nM ADDLs.
- The CK2 inhibitor DMAT completely blocked ADDL-induced loss of both IRs and NMDA receptors; the CaMKII inhibitor KN93 afforded partial protection.
- Insulin at 100 nM partially prevented and 1 μM completely blocked ADDL-induced dendritic IR loss; 1 μM insulin caused a major (≈70%) blockade of ADDL binding, and 100 nM insulin + 10 μM rosiglitazone produced IR levels similar to control or 1 μM insulin.
- Insulin prevented ADDL-induced oxidative stress and 24-h spine degeneration; protection required IR activity, because AG1024 (5 μM) abolished insulin’s ability to block ADDL binding and increased binding when added alone or with insulin.
Methods
- Primary mature hippocampal neuronal cultures were used after 21 DIV and treated at 37 °C for 3 h with 100 nM ADDLs or vehicle; insulin (100 nM or 1 μM) or rosiglitazone (10 μM) was added 30 min before ADDLs, and AG1024 (5 μM) was added 30 min before insulin.
- ADDLs were prepared from Aβ1–42; outcomes were assessed by surface biotinylation/Western blot, immunocytochemistry with IRα and NU4 anti-ADDL antibodies, phalloidin labeling of spines, and dihydroethidium (DHE) for reactive oxygen species.
- Immunofluorescence intensities were analyzed with NIH ImageJ.
Limitations
- The paper states that the nature of the ADDL binding sites “has yet to be determined” and that future identification of proteins lost from the membrane in response to insulin could provide insight into them.
- Evident from the text: all experiments were performed in mature hippocampal neuronal cultures; no in vivo or human data are reported in this study.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 1 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that DMAT, a CK2 inhibitor, completely blocked ADDL-induced loss of both IRs and NMDARs from the dendrites of hippocampal neurons”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II (CaMKII) Mediate ADDL-Induced Loss of IRs and NMDA subtype glutamate receptors (NMDARs).
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These results are consistent with the notion that ADDLs have a selective impact in accelerating the endocytosis of particular surface proteins, such as IRs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > ADDLs Induce Loss of IRs from Neuronal Surfaces.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Decreased binding is the result of downregulation of ADDL binding sites through a mechanism requiring insulin receptor (IR) tyrosine kinase activity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results here support the hypothesis that the beneficial effect of insulin in AD derives at least in part from an acute decrease in ADDL synaptotoxicity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A plausible mechanism of protection is provided by the current finding that rosiglitazone potentiates the ability of insulin to protect synapses against ADDLs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, ADDL-induced loss of IRs might represent an important early mechanism underlying memory impairment and other pathological features of AD.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Casein Kinase 2 (CK2) and Ca2+/Calmodulin-Dependent Kinase II (CaMKII) Mediate ADDL-Induced Loss of IRs and NMDA subtype glutamate receptors (NMDARs).
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Given that insulin protects neurons against AD-causing neurotoxins, it follows that dysfunctional CNS insulin signaling would be an AD risk factor.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“indicating potentiation of insulin protection by rosiglitazone.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Rosiglitazone Potentiates the Neuroprotective Action of Insulin.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results strongly support the hypothesis that insulin signaling plays a role in defending CNS neurons against AD and provide a disease-specific basis for treatments based on stimulating CNS insulin pathways.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The finding that synapse vulnerability to ADDLs can be mitigated by insulin suggests that bolstering brain insulin signaling, which can decline with aging and diabetes, could have significant potential to slow or deter AD pathogenesis.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 7
- Probably not a substantial claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In fact, AG1024 caused significant increases in neuronal ADDL binding both when AG1024 was added alone and in the presence of exogenous insulin.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Protection by Insulin Requires IR Activity.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“We have identified a unique molecular mechanism that protects CNS neurons against ADDLs, soluble neurotoxins putatively responsible for the synaptic deterioration underlying Alzheimer's memory failure.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, physiological insulin and pathological ADDLs negatively regulate the abundance of each other's binding sites, creating a competitive balance between synapse survival and degeneration.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus the mechanism of protection does not involve simple competition between ADDLs and insulin for a common binding site on the neuronal surface, but rather is a signaling-dependent downregulation of ADDL binding sites.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results show that insulin blocks ADDL binding to synapses, thereby preventing the ensuing neurotoxicity.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This indicates that loss of insulin receptors precedes and is not a consequence of overall collapse and retraction of synaptic spines.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Results > Insulin Prevents ADDL-Induced Synapse Loss.
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“An elevated risk for AD also exists in type 2 diabetes patients, who manifest deficient CNS insulin signaling.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
What the sources say
- Not checked yetcites [31] Craft S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr Alzheimer Res. 2007;4:147–152. doi: 10.2174/156720507780362137. [[DOI](https://doi.org/10.2174/156720507780362137)] [[PubMed](https://pubmed.ncbi.nlm.nih.gov/17430239/)] [[Google Scholar](https://scholar.google.com/scholar_lookup?journal=Curr%20Alzheimer%20Res&title=Insulin%20resistance%20and%20Alzheimer's%20disease%20pathogenesis:%20potential%20mechanisms%20and%20implications%20for%20treatment&author=S%20Craft&volume=4&publication_year=2007&pages=147-152&pmid=17430239&do source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Insulin signaling downregulates ADDL binding, while ADDLs downregulate IRs.”
§ Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Internalization occurs by a mechanism mediated by casein kinase 2 (CK2) and Ca2+/calmodulin-dependent kinase 2 (CaMK II), which also are involved in ADDL-induced internalization of NMDA receptors (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Aβ oligomers induce a striking redistribution of IRs, causing their internalization from dendritic membranes and accumulation in the cell body. This renders neurons insulin resistant (De Felice et al., 2009; De Felice et al., 2008; Zhao et al., 2008).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“insulin itself blocks the pathological binding of Aβ oligomers and the resulting redistribution of IRs and synapse loss (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Clustering of oligomers at synapses, moreover, shows a cause-and-effect relationship with characteristic Alzheimer neuropathologies. AD type tau hyperphosphorylation (De Felice et al., 2008), redistribution of insulin receptors (De Felice et al., 2009; Zhao et al., 2008), spine loss (Lacor et al., 2007) and oxidative stress (De Felice et al., 2007; Decker et al., 2010a) are manifest exclusively in”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“pharmacological experiments indicate involvement of CaMKII and casein kinase II (De Felice et al., 2009).”
From The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease (2011) · cites this paper as De Felice et al., 2009
In the citing paper
“Several neuronal receptors have been proposed as mediating the effect of Aβ on synaptic plasticity and memory, including the α-7-nicotinic (16), glutamatergic (39–40), and insulin (14) receptors.”
From Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein (2010) · cites this paper as [14]
In the citing paper
“deteriorations in the clearance and degradation of Aβ as a result of impaired insulin signalling are discussed as a mechanism that increases the risk of AD 135 and may be improved by insulin administration.136,137”
From Intranasal insulin (2021) · cites this paper as [136]
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769
RetractedSoluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744
Alzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506
Self-citationPathways towards and Away from Alzheimer’s Disease
Mattson, M. P. (2004) · Nature · doi:10.1038/nature02621 · Cited by 3,052
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Regulation of NMDA receptor trafficking by amyloid-β
Snyder, E. M., Nong, Y., Almeida, C. G., Paul, S., Moran, T., Choi, E. Y., Nairn, A. C., Salter, M. W., Lombroso, P. J., Gouras, G. K., et al. (2005) · Nature Neuroscience · doi:10.1038/nn1503 · Cited by 1,561 · cited 1×
“We recently reported that ADDLs cause a major loss of IRs from neuronal dendrites (9), in harmony with the impact of ADDLs on other essential plasticity-related neuronal molecules such as N-methylD-aspartate (NMDA) receptors (18, 20).”
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 601–655 of 655
Insulin Action in Brain Regulates Systemic Metabolism and Brain
Kleinridders, A., Ferris, H. A., Cai, W., & Kahn, C. R. (2014)
da Silva, T. (2012) · Americanae (AECID Library)
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Dionísio, P. (2014) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Khosravi, M., Esmaeili, M. H., & Mahin, M. E. (2014)
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.fr.2.115
Johnson, M. (2012) · Materials and Methods · doi:10.13070/mm.ru.2.115
Using TUDCA to treat Alzheimer's disease after pathology onset in APP/PS1 mice
Farmácia, F. D. (2014)
Effects of Insulin on Brain Functioning in Postmenopausal Women
Searles, S. (2016) · ScholarWorks -A service of University of Vermont Libraries (University of Vermont)
Dementia and Insulin Resistance
Bosco, D., Plastino, M., Pirritano, D., Cristiano, D., Colica, C., Ermio, C., Bartolo, M. D., & Fava, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-407824-6.00036-7
Kurudenkandy, F. R. (2016) · Figshare
New Insight into Metallomics in Cognition
Takeda, A., & Tamano, H. (2017) · Springer eBooks · doi:10.1007/978-4-431-56463-8_15
Type II Diabetes and Metabolic Syndrome as Risk Factors for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00005-7
Veränderung von Membranlipiden schützt vor neuronaler Insulinresistenz in Alzheimer-Modellen
Nordström, V., & Herzer, S. (2017) · e-Neuroforum · doi:10.1515/nf-2017-0007
Baluchnejadmojarad, T., Roghani, M., & Kazemloo, P. (2017) · Journal of Advances in Medical and Biomedical Research
Terapia celular y génica con timulina E IGF-1 en modelos animales de neuroinflamación
Villar, M. F. Z. (2018) · El Servicio de Difusión de la Creación Intelectual (National University of La Plata) · doi:10.35537/10915/71572
Exploring the Role of Somatostatin in the Pathogenesis of Alzheimer’s disease
Solarski, M. (2018) · TSpace (University of Toronto)
The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases
Verdile, G., Fraser, P. E., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch4
The Roles of Diffusion and Bulk Flow in Neural Function and Alzheimer's Disease
Dauberman, W. N. (2017)
Insulin resistance, dementia, and depression
Farooqui, A. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819603-8.00008-0
Effects of anle138b treatment on amyloid-β neurotoxicity
Thomas, C. (2020) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-8233
Small Molecular Weight Compounds Antagonistic to Amyloid Peptide25-35
Williams, W. R. (2021) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2021.91004
“Increases in synaptic activity and receptor expression protect against Aβ-associated impairment of synapse function [16] [48].”
BackgroundInfluentialSłomińska, D., Manikowska, K., Hoszman, M., Mikołajczak, P. Ł., & Winiarska, H. (2021) · Pharmacotherapy in Psychiatry and Neurology · doi:10.33450/fpn.2021.02.003
Clarke, J. R., Silva, N. M. L. E., Figueiredo, C. P., Frozza, R. L., Ledo, J. H., Beckman, D., Katashima, C. K., Razolli, D. S., Carvalho, B. M., Frazão, R., et al. (2015) · Americanae (AECID Library) · doi:10.15252/emmm.201404183/abstract
Self-citationJohnson, M. (2012) · 实验材料和方法 · doi:10.13070/mm.cn.2.115
志賀, 英., & 高喜, 三. (2021) · Nihon Bika Gakkai Kaishi (Japanese Journal of Rhinology) · doi:10.7248/jjrhi.60.57
A Review of Proteins Associated With Neuroprotection and Regeneration in Alzheimer's Disease
Agrawal, H., & Mehendale, A. M. (2022) · Cureus · doi:10.7759/cureus.30412
Maladie d’Alzheimer, peptides β-amyloïdes et système ubiquitine-protéasome
Simon, P. Y. R., Bus, J., & David, R. (2023) · médecine/sciences · doi:10.1051/medsci/2023094
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150846
Andrade, L. J. D. O., de Oliveira, G. C. M., & de Oliveira, L. M. (2024) · medRxiv · doi:10.1101/2024.06.21.24309323
Insulin use in diabetes association with cognitive impairment and dementia incidence
Hajihosseini, S., Kurd, D. M., Nouroozi, F., Haghighi, S., Dini, N., Ghobadi, Y., Tehrani, N., Shahrokhi, M., Belbasi, M., Alizadeh, H., et al. (2025) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-025-01042-7
Role of diabetes and altered metabolic homeostasis in age-related dementia
Biswas, T., Ahmed, M. A., Bhowmick, S., & Mondal, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00028-1
Metabolic connections between Alzheimer's disease and diabetes
Adhikary, K., Ganguly, K., Chowdhury, S. R., & Banerjee, P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33355-2.00024-4
Svensson, C. (2011) · DiVA (Stockholm University)
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150870
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150861
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150852
Ali, T., Rehman, S. U., Khan, A., Badshah, H., Abid, N. B., Kim, M. W., Jo, M. H., Chung, S. S., Lee, H.-G., Rutten, B. P. F., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14411201
Qin, G., Dong, Y., Liu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17120186
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150858
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150843
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150855
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150849
Qin, G., Dong, Y., Liu, Z., et al. (2021) · Figshare · doi:10.6084/m9.figshare.17120177
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150864
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14150867
Rôle des ADAM dans le processus physiopathologique de la maladie d'Alzheimer
Laumet, G. O. (2010) · theses.fr (ABES) · doi:10.70675/94126786zf990z488ezb471z5f1d5686766c
Mohammed, S. G. A. A., Qoronfleh, M. W., Alawi, R. A. A., & Al‐Siyabi, S. (2026) · Brain and Behavior · doi:10.1002/brb3.71411 · Cited by 1
“A drastic decrease in the neuronal surface insulin receptors (IRs) was observed following the administration of A β oligomers into the hippocampal region (Zhao et al. 2008 ; De Felice et al. 2009 ).”
InfluentialAzadi, S., Fadaei‐kenarsary, M., Sahebi, K., Baneshi, M., Tajbakhsh, A., Niknahad, H., & Negahdaripour, M. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119553
Pacheco-Sánchez, B., López-Gambero, A. J., Gavito, A., Rivera, P., Suárez, J., Sanjuan, C., Nilsson, P., Tambaro, S., & de Fonseca, F. R. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119629
Díaz, M. L., Tamburini, G., Arriagada, D., Poblete, N., Ardiles, Á. O., Neira, D., Sepúlveda, D., Martínez, G., Gozalvo, R., Arcos, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.11.743979
Self-citationThe Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective
Çataklı, D., Özen, Ö., Tuncgovde, E. B., & Ozsarlak‐Sozer, G. (2026) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.70294
Oxidative Stress and Apoptotic Biomarkers in Diabetic Retinopathy
Al‐Shabrawey, M., & Smith, S. B. (2013) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-007-5971-8_7
Metadata
- Authors
- De Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L.
- Affiliations
- Department of Neurobiology and Physiology, Northwestern University, Evanston, IL 60208; and
- Universidade Federal do Rio de Janeiro (BR)
- Instituto de Bioquímica Médica and
- Northwestern University (US)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-02-10
- Volume
- 106
- Issue
- 6
- Pages
- 1971-1976
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2634809
- OpenAlex
- W2097335530
- Semantic Scholar
- f83fd1ab92993abebf2d284fe60d8398949b7908
- Cited by
- 657
- References
- 51
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 17 · 2023: 20 · 2022: 30 · 2021: 41 · 2020: 41 · 2019: 42 · 2018: 44 · 2017: 42 · 2016: 44 · 2015: 53 · 2014: 44 · 2013: 57 · 2012: 46
- FWCI
- 31.69
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-05-05)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation for the National Institutes of Health
- Howard Hughes Medical Institute
- Alzheimer's Association
- American Health Assistance Foundation
- National Institute on Aging (R01AG022547, R01-AG22547, R01-AG18877, R01AG018877)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, amyloid-beta oligomers, insulin signaling, insulin receptor, synaptic plasticity, oxidative stress, CaMKII, casein kinase 2, rosiglitazone, insulin receptor tyrosine kinase, hippocampal neurons, memory loss
- MeSH terms
- Rosiglitazone, Alzheimer Disease, Animals, Cattle, Cells, Cultured, Hippocampus, Humans, Insulin, Neurons, Protein Binding, Receptor, Insulin, Synapses, Signal Transduction, Amyloid beta-Peptides, Oxidative Stress, Dimerization, Protective Agents, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
